arrow
S

Stephen J. Schuster

University of Pennsylvania
H指数:75
被引数:3.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

出版更正:CD19 CAR T细胞在B细胞淋巴瘤中的十年持久性

2026-08-260
OAAI
Decade-long persistence of CD19 CAR T cells in B cell lymphomas

CD19 CAR T细胞在B细胞淋巴瘤中的十年持续性

2026-08-100
OA
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis

CD19嵌合抗原受体T细胞疗法后出现的迟发性血细胞减少:细胞治疗联盟的分析

2026-06-260
OA
Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance

探究心理困扰与接受主动监测的CLL/SLL患者外周血单核细胞变化之间的关联

2026-05-150
OAAI
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter’s transformation.

Mosunetuzumab单药治疗在复发/难治性Richter’s transformation患者中是有效的且可耐受的。

2026-02-090
OAAI
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells

针对IGHV4-34 b细胞受体的嵌合抗原受体T细胞特异性消除肿瘤性和自身免疫性b细胞

2026-02-040
PRE
cyMAEv2: learning robust cell representations in mass cytometry without supervision
2025-11-010
PRE
Representing immune profiles with self-supervised set representation learning
2025-11-010
PRE
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia

CD19 CAR T细胞疗法在Richter转化中的研究:欧洲慢性淋巴细胞白血病研究倡议进行的 multicentre 回顾性分析

2025-10-220
OAAI
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells

基于定向进化的体内再刺激嵌合抗原受体T细胞配体的发现

2025-08-250
OAAI
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL

评估接受tisagenlecleucel治疗的复发/难治性B-ALL和DLBCL患者体内CAR转座子水平的评价

2025-06-260
OAAI
Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments

自体移植或CAR-T作为MYC重排大B细胞淋巴瘤患者在挽救治疗后缓解期的巩固治疗选择

2025-04-150
PRE
Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sezary syndrome
2025-03-010
PRE
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy

经嵌合抗原受体修饰的T细胞治疗的大b细胞淋巴瘤患者免疫效应细胞相关神经毒性综合征后神经系统症状延长

2025-01-010
PRE
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病后基于维尼托克的治疗效果: 一项国际真实世界研究

2024-12-190
OAAI